NCT03457597View on ClinicalTrials.gov

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

April 15, 2018

Study Completion Date

April 28, 2018

Conditions
Healthy
Interventions
DRUG

Midazolam hydrochloride

Midazolam hydrochloride 2.5 mg

DRUG

Metoprolol tartrate

Metoprolol tartrate 100 mg

DRUG

Pioglitazone hydrochloride

Pioglitazone hydrochloride 15 mg

DRUG

Tolbutamide

Tolbutamide 500 mg

DRUG

Omeprazole

Omeprazole 20 mg

DRUG

Relacorilant

Relacorilant 350mg

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY